Alnylam Pharmace. sell Biotechhunter
Summary
This prediction ended on 11.08.20 with a price of €116.52. With a performance of -1.30%, the SELL prediction by Biotechhunter was trending in the right direction. Biotechhunter has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Alnylam Pharmace. | 4.556% | 4.556% | -23.077% | 21.739% |
iShares Core DAX® | 0.000% | -2.064% | 13.111% | 16.685% |
iShares Nasdaq 100 | 0.626% | -2.884% | 37.744% | 43.441% |
iShares Nikkei 225® | 1.568% | -5.892% | 19.592% | 4.617% |
iShares S&P 500 | 0.334% | -2.281% | 27.745% | 41.046% |
Comments by Biotechhunter for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.